• OPEN AN ACCOUNT
Indian Indices
Nifty
25,694.95 120.60
(0.47%)
Sensex
83,871.32 335.97
( 0.40%)
Bank Nifty
58,138.15 200.60
( 0.35%)
Nifty IT
36,116.90 428.65
( 1.20%)
Global Indices
Nasdaq
47,386.27 378.16
(0.80%)
Dow Jones
6,852.56 102.76
(1.52%)
Hang Seng
50,739.74 -172.02
(-0.34%)
Nikkei 225
9,782.86 100.29
(1.04%)
Forex
USD-INR
88.62 0.00
(0.00%)
EUR-INR
102.49 0.36
(0.35%)
GBP-INR
116.61 0.59
(0.51%)
JPY-INR
0.58 0.00
(0.04%)

EQUITY - MARKET SCREENER

Orchid Pharma Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524372
INE191A01027
247.5375906
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ORCHPHARMA
44.92
4292.1
EPS(TTM)
Face Value()
Div & Yield %
18.84
10
0
 

BCL Enterprises Ltd - Board Meeting Outcome for Outcome Of The Board Meeting Of Held On 28Th May 2025
May 28,2025
This is to inform you that the meeting of Board of Directors of BCL Enterprises Limited (the Company) held today i.e. Wednesday 28th May 2025 took the following items: 1. The Board has considered approved and took on record the Audited Financial Results of the Company including Statement of Assets and Liabilities and Cash Flow Statement along with the Auditors Report of the Statutory Auditor for the fourth quarter and financial year ended 31st March 2025 pursuant to the provisions of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. 2. In compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and SEBI Circular No. CIR/CFD/CMD/56/2016 dated 27th May 2016 we declare that the report of Statutory Auditor is with unmodified opinion with respect to the Audited Financial Results of the Company for the fourth quarter and financial year ended 31st March 2025.